PT1007533E - Bioconjugados e administracao de agentes bioactivos - Google Patents

Bioconjugados e administracao de agentes bioactivos

Info

Publication number
PT1007533E
PT1007533E PT97939382T PT97939382T PT1007533E PT 1007533 E PT1007533 E PT 1007533E PT 97939382 T PT97939382 T PT 97939382T PT 97939382 T PT97939382 T PT 97939382T PT 1007533 E PT1007533 E PT 1007533E
Authority
PT
Portugal
Prior art keywords
bioactive agent
release
site
bioconjugates
cleavage
Prior art date
Application number
PT97939382T
Other languages
English (en)
Portuguese (pt)
Inventor
Charles B Grissom
Frederick G West
Howard W Allen Jr
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Publication of PT1007533E publication Critical patent/PT1007533E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT97939382T 1996-08-27 1997-08-22 Bioconjugados e administracao de agentes bioactivos PT1007533E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2443096P 1996-08-27 1996-08-27
US2503696P 1996-08-27 1996-08-27

Publications (1)

Publication Number Publication Date
PT1007533E true PT1007533E (pt) 2005-09-30

Family

ID=26698439

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97939382T PT1007533E (pt) 1996-08-27 1997-08-22 Bioconjugados e administracao de agentes bioactivos

Country Status (11)

Country Link
US (4) US6315978B1 (cg-RX-API-DMAC7.html)
EP (1) EP1007533B1 (cg-RX-API-DMAC7.html)
JP (1) JP2001501596A (cg-RX-API-DMAC7.html)
AT (1) ATE298344T1 (cg-RX-API-DMAC7.html)
AU (1) AU738431B2 (cg-RX-API-DMAC7.html)
CA (1) CA2264592C (cg-RX-API-DMAC7.html)
DE (1) DE69733618T2 (cg-RX-API-DMAC7.html)
ES (1) ES2244006T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ334870A (cg-RX-API-DMAC7.html)
PT (1) PT1007533E (cg-RX-API-DMAC7.html)
WO (1) WO1998008859A1 (cg-RX-API-DMAC7.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
AU4243700A (en) * 1999-04-16 2000-11-02 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as antitumor agents
KR20020059618A (ko) * 1999-10-15 2002-07-13 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 이미지화제 및 항종양제로서 유용한 코발라민 콘쥬게이트
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
AU785505B2 (en) * 1999-10-15 2009-02-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6797521B2 (en) 1999-10-26 2004-09-28 University Of Utah Research Foundation Fluorescent cobalamins and uses thereof
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
US20020049155A1 (en) * 2000-05-31 2002-04-25 Hogenkamp Henricus P.C. Cobalamin compounds useful as cardiovascular agents and as imaging agents
WO2001092288A2 (en) * 2000-05-31 2001-12-06 Mayo Foundation For Medical Education And Research Cobalamin compounds useful as antibiotic agents and as imaging agents
ES2518926T3 (es) 2000-06-02 2014-11-05 Board Of Regents, The University Of Texas System Conjugados de etilendicisteína y un análogo de glucosa
EP1754712A3 (en) * 2000-10-25 2009-01-14 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
US20020151525A1 (en) * 2000-10-25 2002-10-17 Collins Douglas A. Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation
DE60117043T2 (de) * 2000-11-22 2006-07-13 Rxkinetix, Inc., Louisville Behandlung von mukositis
US20030003114A1 (en) * 2001-03-22 2003-01-02 Pan Xing Qing Enzyme-based anti-cancer compositions and methods
US6752986B2 (en) * 2001-05-24 2004-06-22 The Cleveland Clinic Foundation Composition and methods for affecting metallocorrinoid uptake
US20030031627A1 (en) 2001-07-31 2003-02-13 Mallinckrodt Inc. Internal image antibodies for optical imaging and therapy
JP2005508332A (ja) * 2001-09-28 2005-03-31 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与
US6679827B2 (en) 2001-10-11 2004-01-20 Robert E. Sandstrom Magnetic field enhancement of tumor treatment
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
US7627373B2 (en) 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
WO2004073648A2 (en) * 2003-02-20 2004-09-02 The Cleveland Clinic Foundation Composition and methods for inhibiting cell survival
US7232805B2 (en) * 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
US7119065B2 (en) * 2003-10-29 2006-10-10 Nagoya Industrial Science Research Institute Metal complex-protein composite and oxidation catalyst
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7729761B2 (en) * 2004-07-14 2010-06-01 Cardiac Pacemakers, Inc. Method and apparatus for controlled gene or protein delivery
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
CA2623215A1 (en) * 2004-09-23 2006-12-28 The Regents Of The University Of California Assay for vitamin b12 absorption and method of making labeled vitamin b12
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
EP1893038A1 (en) * 2005-05-17 2008-03-05 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
US8465724B2 (en) * 2005-08-19 2013-06-18 Endocyte, Inc. Multi-drug ligand conjugates
US7774057B2 (en) 2005-09-06 2010-08-10 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression for cardiac protection
CA2635603C (en) * 2005-11-30 2016-01-19 Endo Pharmaceuticals Inc. Treatment of xerostomia
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
US8883723B2 (en) 2007-03-05 2014-11-11 Syracuse University Conjugate of insulin and vitamin B12 for oral delivery
CA2680535C (en) 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
EP2139469A4 (en) * 2007-03-19 2011-09-07 Inflabloc Pharmaceuticals Inc COBALAMINTAXAN bioconjugates
MX2009012370A (es) 2007-05-16 2010-04-22 Ktb Tumorforschungs Gmbh Formulacion de antraciclina de baja viscosidad.
CA2690943A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US8227204B2 (en) * 2007-10-18 2012-07-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8529426B2 (en) * 2007-10-18 2013-09-10 The Invention Science Fund I Llc Ionizing-radiation-responsive compositions, methods, and systems
US8164074B2 (en) * 2007-10-18 2012-04-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
GB2453860B (en) 2007-10-18 2011-03-16 Searete Llc Ionizing-radiation-responsive compositions,methods and systems
US8684898B2 (en) * 2007-10-18 2014-04-01 The Invention Science Fund I Llc Ionizing-radiation-responsive compositions, methods, and systems
US8168958B2 (en) * 2007-10-18 2012-05-01 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US20090104113A1 (en) * 2007-10-18 2009-04-23 Searete Llc Ionizing-radiation-responsive compositions, methods, and systems
US9557635B2 (en) 2007-10-18 2017-01-31 Gearbox, Llc Ionizing-radiation-responsive compositions, methods, and systems
US20090169484A1 (en) 2007-12-28 2009-07-02 Ihi Corporation Iron-salen complex
JP2009274962A (ja) * 2008-05-12 2009-11-26 Yoshihiro Ishikawa 鉄サレン錯体、磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置
US20110166097A1 (en) * 2008-07-21 2011-07-07 Osiris Therapeutics, Inc. Taxane compounds for treating eye disease
CN104800195A (zh) * 2008-11-20 2015-07-29 株式会社Ihi 自磁性金属salen络合物
US9603940B2 (en) * 2010-04-06 2017-03-28 Ihi Corporation Metal salen complex derivative and process for production thereof
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
CN103501821A (zh) 2011-03-08 2014-01-08 艾克塞斯制药公司 用于递送活性剂穿过生物膜的靶向纳米载体系统
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
IN2015DN04147A (cg-RX-API-DMAC7.html) 2012-10-16 2015-10-16 Endocyte Inc
WO2014160305A1 (en) * 2013-03-14 2014-10-02 Albany Molecular Research, Inc. Ligand-therapeutic agent conjugates and silicon-based linkers
JP2016516774A (ja) * 2013-04-08 2016-06-09 ユニバーシティー オブ ノースキャロライナ アット チャペル ヒルＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 光応答性化合物
TWI664187B (zh) * 2013-05-22 2019-07-01 阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
CN105658230B (zh) * 2013-08-29 2020-04-21 希望之城 细胞穿透缀合物及其使用方法
GR20130100654A (el) * 2013-11-22 2015-06-18 Χρηστος Γκολφινου Ταπεινος Επιφανειακως τροποποιημενα πολλαπλως αποκρινομενα σε ερεθισματα νανο/μικρο-δοχεια ως φορεις φαρμακων για στοχευμενη θεραπεια διαφορων μορφων καρκινου
US20220062418A1 (en) * 2018-11-29 2022-03-03 The Trustees Of Dartmouth College Tumor targeting vitamin b12 derivatives for x-ray activated chemotherapy
GB202018713D0 (en) 2020-11-27 2021-01-13 Quadram Inst Bioscience Methods and compositions utilising vitamin b12 binding

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758421A (en) * 1985-03-15 1988-07-19 The Board Of Trustees Of The Leland Stanford Junior University Bleomycin conjugates and method
NZ217821A (en) 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
EP0394277B1 (en) 1987-07-15 1998-01-14 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
US5047227A (en) * 1988-02-08 1991-09-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds
AU5356490A (en) * 1989-04-03 1990-11-05 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
SG50426A1 (en) * 1993-05-20 1998-07-20 Biotech Australia Pty Ltd Lhrh antagonists
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
WO1995027723A1 (en) * 1994-04-08 1995-10-19 Receptagen Corporation Receptor modulating agents and methods relating thereto
US5574018A (en) * 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins

Also Published As

Publication number Publication date
EP1007533A1 (en) 2000-06-14
AU738431B2 (en) 2001-09-20
CA2264592C (en) 2012-02-21
WO1998008859A1 (en) 1998-03-05
US20020111294A1 (en) 2002-08-15
DE69733618D1 (de) 2005-07-28
ES2244006T3 (es) 2005-12-01
CA2264592A1 (en) 1998-03-05
JP2001501596A (ja) 2001-02-06
US20020049154A1 (en) 2002-04-25
AU4148297A (en) 1998-03-19
EP1007533B1 (en) 2005-06-22
US6776976B2 (en) 2004-08-17
US20020115595A1 (en) 2002-08-22
EP1007533A4 (en) 2002-08-07
ATE298344T1 (de) 2005-07-15
US6777237B2 (en) 2004-08-17
NZ334870A (en) 2000-12-22
US6790827B2 (en) 2004-09-14
DE69733618T2 (de) 2006-05-11
US6315978B1 (en) 2001-11-13

Similar Documents

Publication Publication Date Title
PT1007533E (pt) Bioconjugados e administracao de agentes bioactivos
IL141141A0 (en) Targeting pharmaceutical agents to injured tissues
PH12016500941A1 (en) Protection, restoration, and enhancement for erythropoietin-responsive cells, tissues and organs
ATE264114T1 (de) Zyklodexrinpolymere zum gebrauch als medikamententräger
BR9912053A (pt) Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
ID26042A (id) Turunan-turunan asam lemak dari asam-asam empedu dan asam empedu
DE59611341D1 (de) Verwendung von saccharid-konjugaten
AU1766499A (en) Use of an ultrasonic transducer for echographic exploration of human or animal body tissues or organs in particular of the eyeball posterior segment
WO2005097219A3 (en) Ecm-based graft material
EP2311490A3 (en) Uses of antibodies to aminophospholipids for cancer treatment
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
MXPA02011142A (es) Plataforma de nanodispositivo multifuncional.
WO2000045856A3 (en) Novel methods of imaging and treatment with targeted compositions
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
DE69813553D1 (de) Anwendung von akustooptischen und sonolumineszenten kontrastmitteln in diagnostischen verfahren
ES2107041T3 (es) Variantes de activador de plasminogeno tisular obtenidos por glicosilacion, que presentan propiedades terapeuticas.
KR100537343B1 (ko) 관절염 치료용 초음파 장치
AU2001248301A1 (en) Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin
WO2004027045A3 (en) Polymer-linker-drug conjugates for targeted drug delivery
US5490991A (en) Directed delivery of radioprotectants using a receptor specific carrier
GT200000035AA (es) Derivados de resorcinol, (solicitud fraccionaria no. 1 derivada de la patente pi-2000-0035)
ATE425770T1 (de) Kontrastmittel
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
AR029446A1 (es) Un derivado de biciclohexano, su utilizacion, una composicion farmaceutica que lo comprende, un procedimiento para la preparacion de un derivado de biciclohexano y un metodo para modular la funcion del receptor de glutamato metabotropico en un mamifero que requiera tratamiento
EP1520588A3 (en) Uses of antibodies to aminophospholipids for cancer treatment